title: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
authors.affiliation: Hôpital Huriez, CHRU, Lille, France.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.forename: G
authors.initials: G
authors.lastname: Fouquet
authors.forename: B
authors.initials: B
authors.lastname: Hebraud
authors.forename: M
authors.initials: M
authors.lastname: Roussel
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: M L
authors.initials: ML
authors.lastname: Chrétien
authors.forename: B
authors.initials: B
authors.lastname: Arnulf
authors.forename: R
authors.initials: R
authors.lastname: Szalat
authors.forename: L
authors.initials: L
authors.lastname: Garderet
authors.forename: L
authors.initials: L
authors.lastname: Benajiba
authors.forename: B
authors.initials: B
authors.lastname: Pegourie
authors.forename: C
authors.initials: C
authors.lastname: Regny
authors.forename: B
authors.initials: B
authors.lastname: Royer
authors.forename: A
authors.initials: A
authors.lastname: Caulier
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: S
authors.initials: S
authors.lastname: Garciaz
authors.forename: C
authors.initials: C
authors.lastname: Touzeau
authors.forename: C
authors.initials: C
authors.lastname: Chaleteix
authors.forename: J P
authors.initials: JP
authors.lastname: Fermand
authors.forename: H A
authors.initials: HA
authors.lastname: Loiseau
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: P
authors.initials: P
authors.lastname: Moreau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage; D014182:Transplantation, Autologous
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone